Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest
Medical Oncology · 2025
DOI: 10.1007/s12032-025-02875-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2025. Verfasst von Kuan-Ting Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Apoptosis, Drug Resistance, Neoplasm, Oleanolic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: I-Shou University, National Science and Technology Council, Kaohsiung Municipal Ta-Tung Hospital.
Abstract (Originalsprache)
Glioblastoma is the most malignant primary brain tumor. It is characterized by high cellular heterogeneity, which contributes to its high chemoresistance and recurrence rate. To investigate the anticancer effect of RTA-408 on TMZ-resistant glioblastoma, we developed 2 TMZ-resistant cell lines, GBM841R and U-87MGR. Our findings revealed that RTA-408 (Omaveloxolone) effectively inhibited growth, induced cytotoxicity, and reduced colony formation in TMZ-resistant glioblastoma cells. RTA-408 treatment also induced dose-dependent cell cycle arrest, increasing the proportion of cells in the G1 phase while reducing that of those in the G2/M phase. Moreover, RTA-408 enhanced apoptosis and caspase-3 activation in TMZ-resistant cells. Next-generation sequencing revealed that RTA-408 modulated the expression of Nrf2-Keap1-ARE downstream genes in both TMZ-resistant and TMZ-sensitive glioblastoma cells. Western blot analysis revealed that RTA-408 modulated apoptosis-related protein expression and inhibited reactive oxygen species production, thereby reducing oxidative stress in TMZ-resistant glioblastoma cells. These findings indicate that RTA-408 is not only a promising alternative for TMZ-sensitive glioblastoma but also a first-line treatment option for TMZ-resistant glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Department of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- School of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Graduate Institutes of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. taihsintsai@gmail.com.
- Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. taihsintsai@gmail.com.
Förderung
- I-Shou University
- National Science and Technology Council
- Kaohsiung Municipal Ta-Tung Hospital
Zitieren
APA
Lee, K. T., Lieu, A. S., Lin, C. L., Hsu, Y. C., & Tsai, T. H. (2025). Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest. Medical Oncology. https://doi.org/10.1007/s12032-025-02875-2
Vancouver
Lee KT, Lieu AS, Lin CL, Hsu YC, Tsai TH. Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest. Medical Oncology. 2025. doi:10.1007/s12032-025-02875-2
BibTeX
@article{Lee2025,
author = {Lee, Kuan-Ting and Lieu, Ann-Shung and Lin, Chih-Lung and Hsu, Yi-Chiang and Tsai, Tai-Hsin},
title = {Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest},
journal = {Medical Oncology},
year = {2025},
doi = {10.1007/s12032-025-02875-2}
}
EUVIMED